Prader-Willi Syndrome Pipeline Summary

DelveInsight’s, “Prader-Willi Syndrome - Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Prader-Willi Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Prader-Willi Syndrome: Understanding

Prader-Willi Syndrome: Overview

Prader-Willi syndrome (PWS) is a rare, complex genetic disorder affecting the metabolic, endocrine, and neurological systems. It is characterized by severe hypotonia and feeding difficulties during infancy, followed by developmental delay, hyperphagia (excessive eating), impaired satiety, and progressive obesity. Hypothalamic dysfunction also contributes to endocrine abnormalities such as growth hormone deficiency, hypogonadism, hypothyroidism, and, less commonly, central adrenal insufficiency.

PWS results from the absence of expression of paternally inherited genes in the chromosome 15q11.2–q13 region. Approximately 70% of cases are associated with a paternal deletion, around 25% with maternal uniparental disomy (both chromosome 15 copies inherited from the mother), and a smaller proportion with defects in the genomic imprinting center.

The loss of paternally expressed genes disrupts normal hypothalamic function, leading to impaired regulation of appetite, energy expenditure, and multiple endocrine pathways. This produces the characteristic progression from neonatal hypotonia and poor feeding to hyperphagia, impaired satiety, and severe obesity. Abnormal neuropeptide signaling, including alterations in the oxytocin and ghrelin systems, contributes to hyperphagia, while hypothalamic dysfunction can cause growth hormone deficiency, hypogonadism, hypothyroidism, and central adrenal insufficiency.

Diagnosis is primarily confirmed through molecular genetic testing. DNA methylation analysis is the recommended initial test and can detect more than 99% of PWS cases. If positive, additional genetic testing can determine whether the underlying mechanism is a paternal deletion, maternal uniparental disomy, or an imprinting defect. Chromosome analysis/FISH and chromosomal microarray may be used for further genetic characterization. Additional assessments may include thyroid function, glucose and HbA1c testing, sleep studies, and bone mineral density evaluation.

Management of PWS is lifelong and multidisciplinary, focusing on controlling hyperphagia and obesity, addressing endocrine abnormalities, and supporting developmental and behavioral needs. Nutritional management and strict control of food access are essential, while physical and occupational therapy can improve hypotonia and motor development. Recombinant human growth hormone can improve growth, muscle strength, physical function, and bone density. Hormone replacement may be required for hypogonadism, and associated conditions such as hypothyroidism, diabetes, sleep-disordered breathing, and behavioral or psychiatric disorders should be monitored and treated. In March 2025, the FDA approved VYKAT XR (diazoxide choline) for hyperphagia in adults and children aged 4 years and older with PWS.

"Prader-Willi Syndrome- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Prader-Willi Syndrome pipeline landscape is provided which includes the disease overview and Prader-Willi Syndrome treatment guidelines. The assessment part of the report embraces, in depth Prader-Willi Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prader-Willi Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Prader-Willi Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Prader-Willi Syndrome.

Prader-Willi Syndrome Emerging Drugs Chapters

This segment of the Prader-Willi Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Prader-Willi Syndrome Emerging Drugs

• Pitolisant: Harmony Biosciences

Pitolisant is a high-affinity inverse agonist at the H3 receptor, which normally inhibits histamine synthesis and release. By preventing endogenous histamine from binding to these receptors, pitolisant increases histaminergic activity in the central nervous system, thereby enhancing wakefulness. It also modulates the release of other neurotransmitters, contributing to its stimulating effects without the higher abuse potential associated with traditional stimulants like amphetamines. The drug has received Orphan Drug Designation from the FDA and is currently in Phase III stage of its development for the treatment of Prader-Willi syndrome.

• BMB-101: Bright Minds Biosciences

BMB-101 is an investigational, novel scaffold 5-HT?C receptor Gq-protein-biased agonist being evaluated for Prader-Willi syndrome (PWS), particularly to address hyperphagia and associated behavioral symptoms. It selectively activates the 5-HT?C receptor through the Gq-protein signaling pathway while minimizing ?-arrestin recruitment, which is intended to reduce receptor desensitization and tolerance during chronic treatment. In PWS, genetic alterations can result in reduced 5-HT?C receptor function, providing a rationale for enhancing 5-HT?C signaling. By stimulating 5-HT?C-mediated signaling, BMB-101 is intended to modulate appetite and behavioral pathways and potentially reduce hyperphagia and related behavioral abnormalities in Prader-Willi Syndrome. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Prader-Willi Syndrome.

• RM 718: Rhythm Pharmaceuticals

RM-718 is an investigational synthetic cyclic heptamer peptide and selective melanocortin-4 receptor (MC4R) agonist being evaluated for Prader-Willi syndrome (PWS), including its severe hyperphagia and obesity. It is formulated as a sustained-release, once-weekly subcutaneous injection. RM-718 acts by selectively activating MC4R, a key receptor in the hypothalamic melanocortin pathway that regulates appetite, energy expenditure, and body weight. By stimulating MC4R signaling, RM-718 is intended to enhance satiety, reduce excessive food intake (hyperphagia), and potentially improve energy balance and obesity associated with PWS. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Prader-Willi Syndrome.

• CCT 987: Canary Cure Therapeutics

CCT-987 is a first-in-class, dual-action RNA therapeutic being developed for Prader-Willi syndrome (PWS). The drug is designed to directly correct peripheral adipose biology by delivering a payload of CB1R siRNA and leptin mRNA directly to subcutaneous adipose tissue. The dual RNA therapy is intended to clear the CB1R molecular blockade and deliver a physiological pulse of leptin, thereby re-engaging the hypothalamic satiety circuit and promoting fat loss while enhancing lean muscle mass. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Prader-Willi Syndrome.

Further product details are provided in the report……..

Prader-Willi Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Prader-Willi Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Prader-Willi Syndrome

There are approx. 20+ key companies which are developing the therapies Prader-Willi Syndrome. The companies which have their Prader-Willi Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Harmony Biosciences, and others.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Prader-Willi Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Prader-Willi Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Prader-Willi Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prader-Willi Syndrome drugs.

Prader-Willi Syndrome Report Insights

• Prader-Willi Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Prader-Willi Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Prader-Willi Syndrome drugs?
• How many Prader-Willi Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prader-Willi Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Prader-Willi Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Prader-Willi Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Harmony Biosciences
• ConSynance Therapeutics
• Bright Minds Biosciences
• Canary Cure Therapeutics
• Rhythm Pharmaceuticals
• Tonix Pharmaceuticals
• Palobiofarma
• Relmada Therapeutics, Inc.

Key Products

• Pitolisant
• CSTI-500
• BMB-101
• CCT 987
• RM 718
• TNX-2900
• PBF-999
• Sepranolone
• Setmelanotide
• BMB-105